Latest News and Press Releases

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA)...

PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathyIND clearance follows the granting of European Medicine Agency (EMA)...

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people...

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis Europe and will lead the Company as it advances pioneering kidney disease...

Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002, as an important novel modality to treat IgAN Data support progression towards a Phase I/II...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...

Purespring Therapeutics presents preclinical data at the 61st ERA Congress Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to replace defective genes or to...

Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer Appointments of Fredrik and Peter complete build-out of senior team London— 6 September...